List of Excipients in Branded Drug CHILDRENS LORATADINE ODT

Generic Drugs Containing CHILDRENS LORATADINE ODT

Company	Ingredient	NDC	Excipient
WALGREEN CO	loratadine	0363-4020	ASPARTAME
WALGREEN CO	loratadine	0363-4020	CELLULOSE, MICROCRYSTALLINE
WALGREEN CO	loratadine	0363-4020	CROSPOVIDONE
WALGREEN CO	loratadine	0363-4020	MANNITOL

What are the Most Frequently-Used Excipients in CHILDRENS LORATADINE ODT?

# Of NDCs	Excipient
1	ASPARTAME
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	MANNITOL

Children's Loratadine ODT Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Children's loratadine orally disintegrating tablets are an established OTC dosage-form opportunity with low active-ingredient cost, broad consumer recognition, and limited composition-of-matter patent risk. The commercial challenge is not loratadine discovery. It is delivering a pleasant-tasting, rapidly disintegrating, mechanically robust tablet at a competitive cost while maintaining regulatory compliance and stable supply.

The strongest product concepts are 5 mg pediatric ODTs for children aged 2 to under 6 years, 10 mg ODTs for children aged 6 years and older, and differentiated unit-dose products designed for travel, school, and households that avoid liquid medicines. Excipient selection should prioritize taste masking, saliva-triggered disintegration, low friability, moisture control, and pediatric acceptability.

What is Children's Loratadine ODT?

Children's loratadine ODT is a solid oral dosage form containing loratadine that disintegrates on the tongue without water. Loratadine is a second-generation, non-sedating antihistamine indicated for temporary relief of allergy symptoms, including sneezing, rhinorrhea, itchy or watery eyes, and nasal or throat itching.

U.S. OTC labeling generally distinguishes dosing by age and strength:

Product strength	Typical pediatric positioning	Commercial relevance
5 mg	Children aged 2 to under 6 years, subject to product labeling	Primary pediatric strength
10 mg	Children aged 6 years and older and adults	Broadest volume opportunity
5 mg/5 mL liquid	Children who cannot swallow solid dosage forms	Main competing format
10 mg ODT	Older children and adults	Family-use and convenience format

The exact dose, age cutoff, warnings, and directions must follow the applicable FDA regulatory pathway and final product labeling. Loratadine is regulated as an OTC antihistamine under FDA monograph requirements, including 21 C.F.R. § 341. Loratadine products also may be marketed under approved applications, depending on the product and sponsor.

What excipients are suitable for a pediatric loratadine ODT?

A practical excipient system combines a water-soluble or rapidly wetting filler, a superdisintegrant, a sweetener, a flavor system, a lubricant, and a moisture-control strategy.

Functional requirement	Candidate excipients	Primary development purpose
Tablet matrix	Mannitol, xylitol, sorbitol, microcrystalline cellulose	Mouthfeel, compressibility, dilution, bulk
Rapid disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Tablet breakup in saliva
Taste management	Sucralose, aspartame, acesulfame potassium, flavor systems	Reduce bitterness and chemical aftertaste
Mouthfeel	Mannitol, xylitol, low levels of microcrystalline cellulose	Cooling sensation and reduced grittiness
Binding	Copovidone, povidone, low-substituted hydroxypropyl cellulose	Improve tablet strength
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduce ejection force and sticking
Flow control	Colloidal silicon dioxide	Improve powder flow and content uniformity
Saliva interaction	Poloxamers or wetting aids, where justified	Support dispersion of poorly soluble drug
Stability control	Low-water excipients, moisture-barrier packaging	Reduce degradation and tablet softening

Mannitol is usually the leading diluent for pediatric ODTs because it compresses well, dissolves readily, and produces a cooling mouthfeel. That sensory effect can improve acceptability, although excessive mannitol may increase hygroscopicity or produce an overly intense cooling sensation.

Crospovidone is often suitable for direct-compression ODTs because it promotes rapid liquid uptake and tends to produce less gel formation than some alternative disintegrants. Croscarmellose sodium can also be effective, but its level and particle size require optimization to avoid excessive tablet swelling or a rough mouthfeel.

Microcrystalline cellulose can improve mechanical strength, but high levels may create a chalky or fibrous oral texture. A blend of mannitol and a limited amount of microcrystalline cellulose is more likely to balance tablet hardness with pediatric mouthfeel than either material used alone.

How should loratadine bitterness be managed in an ODT?

Taste masking is the central formulation issue. Loratadine has low aqueous solubility and can produce a bitter or medicinal perception when the tablet wets in the mouth. The formulation must limit drug dissolution in saliva while allowing appropriate gastrointestinal release after swallowing.

Taste-masking approaches

The main approaches are:

1. Polymer coating or microencapsulation of loratadine particles.
2. Drug-resin complexation.
3. pH-modifying systems that reduce apparent bitterness.
4. Sweetener and flavor systems.
5. A combination of physical barrier and sensory masking.

Sweeteners alone are unlikely to provide a robust taste-masking solution if the drug rapidly contacts taste receptors. A coated-particle approach may provide better control but adds manufacturing steps, process validation requirements, and potential effects on dissolution.

Drug-resin complexes may improve taste but can create concerns regarding release, content uniformity, resin capacity, and scale-up. They may be attractive where a sponsor seeks a differentiated formulation, but the resulting product must demonstrate that the complex does not delay or reduce loratadine exposure.

Aspartame can be effective in pediatric ODTs but requires appropriate labeling for individuals with phenylketonuria. Sucralose avoids that specific warning and has strong sweetness at low use levels. A combination of sucralose with a high-intensity flavor system can reduce the total sweetener load.

Flavor selection should be tested against the drug's aftertaste rather than evaluated only as a standalone flavor. Fruit profiles such as grape, cherry, berry, and orange are common, but flavor acceptance can vary by age group and market.

What manufacturing process is best for Children's Loratadine ODT?

Direct compression is usually the lowest-cost manufacturing route if the loratadine particle properties, excipient flow, and tablet strength are acceptable. It minimizes processing steps and avoids water or solvent exposure.

A typical direct-compression process includes:

• Screening and deagglomeration of excipients.
• Preblending of loratadine with part of the filler.
• Addition of superdisintegrant, sweetener, flavor, and flow aid.
• Lubrication with controlled shear and time.
• Compression at a force sufficient to maintain handling strength.
• Blister or high-barrier bottle packaging.

Wet granulation is generally less attractive because moisture can affect ODT performance, increase processing cost, and complicate taste-masking coatings. Dry granulation may improve flow and uniformity but can raise tablet density and slow disintegration.

Critical quality attributes

The core quality attributes are:

Attribute	Commercial and regulatory significance
Disintegration time	Determines the ODT performance claim
Hardness and friability	Controls breakage during packaging and transport
Assay and content uniformity	Important because pediatric doses may contain only 5 mg of loratadine
Dissolution	Confirms drug release and supports equivalence
Water activity	Predicts stability and packaging performance
Taste and mouthfeel	Strong driver of pediatric adherence
Particle-size distribution	Affects blend uniformity, dissolution, and taste
Residual solvents	Relevant for coated or encapsulated drug particles

The optimal product is not necessarily the fastest-disintegrating tablet. A tablet that disintegrates in seconds but leaves a bitter residue may perform worse commercially than a slightly slower tablet with superior taste and mouthfeel.

What regulatory pathway applies to Children's Loratadine ODT?

Loratadine is an OTC antihistamine active ingredient recognized under the FDA OTC framework. The regulatory route depends on whether the proposed product conforms to the applicable monograph conditions or is submitted through an approved application.

For a U.S. product, the sponsor must control:

• Active ingredient identity, strength, and quality.
• Permitted indication and labeling.
• Age-specific dosing.
• Warnings and directions.
• Manufacturing under current good manufacturing practices.
• Stability through the labeled shelf life.
• Dissolution and dosage-form performance.
• Excipients and color additives permitted for the intended use.

Pediatric products require special attention to excipient exposure. FDA's inactive ingredient database is a useful screening tool, but prior use of an excipient does not automatically establish suitability for every age group, strength, route, or daily exposure. Pediatric excipient assessment should consider total daily intake, repeated use during allergy season, metabolic limitations, allergy risks, and sensory tolerability.

FDA regulatory status and OTC positioning

An ODT product may be positioned as:

• A monograph-compliant OTC product.
• A private-label or store-brand OTC product.
• A branded OTC product.
• A line extension under an approved application, where applicable.

The commercial advantage of the monograph pathway is reduced dependence on a traditional new-drug development strategy. The limitation is that the product must remain within the permitted active ingredient, indication, strength, dosage form, and labeling framework.

What patents protect Children's Loratadine ODT?

Loratadine's composition-of-matter patent protection has expired in the United States. The original Claritin product was developed by Schering-Plough, later associated with Bayer's consumer-health portfolio. Generic and private-label loratadine products have been marketed for many years.

The remaining IP risk is more likely to involve:

• Specific ODT compositions.
• Taste-masked loratadine particles.
• Manufacturing processes.
• Particle-size control.
• Packaging systems.
• Combination products.
• Brand trademarks and trade dress.
• Product-specific formulation patents held by individual sponsors.

There is no single patent estate that protects the entire category of Children's Loratadine ODT products. Patent analysis must be performed at the identified product, assignee, formulation, and jurisdiction level.

Orange Book status

The Orange Book is not a complete catalog of all OTC loratadine products. Products marketed under the OTC monograph framework generally do not create the same Orange Book listing profile as prescription NDA products. An individual approved application may have listed patents, but a monograph-compliant private-label ODT should not be assumed to have an Orange Book patent barrier.

A sponsor should assess:

• Whether the reference product is an approved NDA product or monograph product.
• Whether the proposed product relies on an ANDA, an approved application, or monograph compliance.
• Whether any formulation or method-of-use patents are listed for the relevant reference product.
• Whether the proposed label overlaps with protected uses.

When does Children's Loratadine ODT lose exclusivity?

The core active-ingredient exclusivity for loratadine has already expired. The commercial exclusivity of a new ODT product therefore depends on factors other than basic loratadine protection.

Exclusivity or barrier	Current category relevance
Composition-of-matter patent	Expired
Basic loratadine generic entry	Established
Pediatric ODT formulation patent	Product-specific and potentially relevant
Taste-masking patent	Potentially relevant if claims are narrow and valid
Trademark	Relevant to branded products
Retailer private-label agreement	Commercial rather than statutory exclusivity
Manufacturing know-how	Can delay replication but does not block all competitors
FDA regulatory exclusivity	Generally limited for an established OTC active ingredient

A new ODT can obtain a period of practical market exclusivity through retailer contracts, supply reliability, distinctive packaging, taste performance, or a defensible formulation patent. Those advantages are more vulnerable than composition-of-matter protection.

Are Paragraph IV challenges relevant to loratadine ODT?

Paragraph IV litigation is relevant only if the product is tied to an approved application with listed patents and the sponsor files an ANDA referencing that application. It is not automatically applicable to every OTC monograph product.

For a monograph-compliant loratadine ODT, the principal legal risks are more likely to be:

• Patent infringement allegations based on formulation claims.
• Trademark disputes.
• Trade-dress claims.
• Regulatory objections to labeling or active-ingredient presentation.
• Contract disputes involving private-label supply.

A generic sponsor developing an ODT should conduct a claim-by-claim freedom-to-operate review covering coated particles, taste-masking systems, excipient ratios, compression processes, and packaging claims. Patent expiry dates cannot be inferred from the product name alone.

What commercial opportunities exist for Children's Loratadine ODT?

The strongest opportunities are in convenience, adherence, and channel-specific packaging rather than therapeutic differentiation.

Pediatric 5 mg ODT

A 5 mg ODT targeted to children aged 2 to under 6 years can compete with liquids by eliminating measuring devices, spills, and dosing-volume concerns. The product must have a low tablet mass, rapid wetting, and strong taste acceptance.

Family-strength 10 mg ODT

A 10 mg ODT can address older children, adolescents, and adults. A dual-strength family line can simplify retail merchandising and manufacturing while supporting a single brand architecture.

Travel and on-the-go packaging

Unit-dose blister packaging creates a clear use case for:

• Travel.
• School bags.
• Sports activities.
• Outdoor exposure.
• Households without immediate access to water.

Child-resistant packaging requirements must be reconciled with ease of access for caregivers. Blister design, peel strength, moisture barrier, and tablet protection are critical.

Private-label retail programs

Retailers and pharmacy chains may seek an ODT product with:

• Competitive landed cost.
• Stable year-round supply.
• A distinct flavor profile.
• A 5 mg pediatric SKU.
• A 10 mg family SKU.
• Packaging compatible with store-brand planograms.

Because loratadine is a mature generic active ingredient, manufacturing efficiency and supply assurance have high commercial value.

E-commerce and subscription channels

ODTs are well suited to e-commerce because they are lighter and less prone to leakage than liquids. Moisture-protective packaging and controlled shelf-life data are essential for distribution through variable warehouse and shipping conditions.

How does loratadine ODT compare with liquid and chewable products?

Attribute	Loratadine ODT	Loratadine liquid	Loratadine chewable
Water required	No	No	No
Dose flexibility	Moderate	High	Low to moderate
Measuring-device risk	Low	Higher	Low
Taste exposure	Immediate	Prolonged but dilute	Immediate
Packaging burden	Moisture-sensitive	Leak risk and larger volume	Moderate
Manufacturing cost	Moderate	Often lower formulation complexity	Moderate
Pediatric acceptance	Highly taste-dependent	Depends on flavor and dosing volume	Highly taste-dependent
Travel convenience	High	Low to moderate	High

ODT has a stronger convenience proposition than liquid and a stronger dosing-control proposition than many chewables. Liquid remains difficult to displace for children requiring flexible dose adjustment or those unable to tolerate a solid tablet.

How strong is the patent estate for a new Children's Loratadine ODT?

The category-level patent estate is weak because the active ingredient is mature and broadly genericized. A new product can still establish a moderate formulation position if it uses a non-obvious combination of:

• Loratadine particle engineering.
• Coated drug particles.
• Specific excipient ratios.
• Rapid disintegration with adequate hardness.
• Controlled moisture exposure.
• Improved taste performance.
• A manufacturing process that consistently produces the claimed attributes.

Patent strength will depend on claim breadth, written-description support, enablement, prior art, and the ability to prove infringement from commercial product testing. Narrow claims limited to a particular sweetener or ordinary ODT excipient may have limited blocking value.

Trade secrets may be more practical than patents for flavor ratios, coating parameters, compression settings, and process controls. Trade-secret protection does not prevent independent development, but it can preserve product performance advantages when reverse engineering is difficult.

What generic launch risks exist for Children's Loratadine ODT?

The principal launch risks are commercial and technical:

1. Failure to achieve acceptable taste at the target drug loading.
2. Tablet breakage during high-speed packaging.
3. Moisture uptake and loss of disintegration performance.
4. Inconsistent 5 mg content uniformity.
5. Excessive tablet size for young children.
6. Inadequate dissolution after taste-masking treatment.
7. Retail price compression from established generic suppliers.
8. Seasonal demand concentration.
9. Supply interruptions involving mannitol, flavors, coating polymers, or blister materials.
10. Labeling or age-positioning errors.

Seasonality affects forecast accuracy. Allergy demand can be concentrated in spring and early summer, with regional variation. A sponsor should plan production, inventory, and promotional activity around seasonal sell-through rather than annual average demand.

What licensing and partnership opportunities exist?

Licensing opportunities are most likely to involve formulation technology rather than loratadine itself. Potential transaction structures include:

• Licensing a taste-masked loratadine particle platform.
• Contract development and manufacturing of pediatric ODTs.
• Private-label supply agreements with retailers.
• Regional commercialization rights.
• Co-development of a pediatric allergy product line.
• Acquisition of a formulation patent family or manufacturing package.

A transaction should distinguish between ownership of the final formulation, ownership of process know-how, rights to flavor systems, and access to validated manufacturing capacity. A formulation license with no reliable commercial manufacturing route has limited value in a price-sensitive OTC market.

What is the commercial outlook for Children's Loratadine ODT?

The market opportunity is a lifecycle-management and consumer-convenience play, not a high-margin protected-drug opportunity. The most defensible proposition combines a 5 mg pediatric product, a 10 mg family product, strong taste performance, moisture-protective unit-dose packaging, and retailer-ready supply economics.

The commercial case improves when the product can demonstrate:

• Faster and cleaner administration than liquid.
• Better portability than liquid.
• More reliable dose delivery than measured syrup.
• Acceptable taste without excessive sweetener.
• Shelf stability across distribution conditions.
• A cost structure close to standard generic tablets.

Key Takeaways

• Loratadine's core patent protection has expired, and generic competition is established.
• Children's loratadine ODT value depends on formulation performance, taste, packaging, and supply economics.
• Mannitol, crospovidone, controlled sweetener use, and moisture-barrier packaging are strong starting points.
• Taste masking should be designed as a formulation system, not treated as a flavor-only problem.
• A 5 mg pediatric ODT offers the clearest product differentiation against liquid formulations.
• A 10 mg ODT supports family branding and manufacturing scale.
• Orange Book and Paragraph IV analysis is product-specific and depends on the regulatory pathway.
• Formulation patents may create targeted protection, but they are unlikely to provide broad category exclusivity.
• Retailer private-label programs, travel packaging, and e-commerce distribution are the main commercial opportunities.
• Manufacturing know-how and sensory performance may provide more practical advantage than narrow excipient patents.

FAQs About Children's Loratadine ODT

Is loratadine ODT suitable for children under two years old?

OTC loratadine labeling generally does not establish routine use for children under two years of age without appropriate medical direction. A product should not extend pediatric age claims beyond its supported labeling.

Can a loratadine ODT be made without sugar?

Yes. Sugar-free systems can use mannitol, sucralose, acesulfame potassium, and suitable flavors. The formulation still requires testing for sweetness, aftertaste, tablet strength, and moisture stability.

Does an ODT require a special loratadine patent?

No. An ODT can be developed without a loratadine composition-of-matter patent. A sponsor must still assess third-party formulation, process, packaging, trademark, and trade-dress rights.

Is a loratadine ODT bioequivalent to a standard loratadine tablet?

The dosage form may differ in disintegration and in-mouth exposure, but systemic performance must meet applicable regulatory requirements. Taste masking, particle coating, and excipient selection can affect dissolution and exposure.

What packaging is best for pediatric loratadine ODTs?

Aluminum-aluminum or another validated high-barrier blister is generally preferable when moisture sensitivity threatens tablet strength or disintegration. Packaging selection must also address child resistance, unit-dose convenience, and transport durability.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. Food and Drug Administration. (2016). E6(R2) good clinical practice: Integrated addendum to ICH E6(R1). https://www.fda.gov/regulatory-information

5. European Medicines Agency. (2013). Reflection paper on the pharmaceutical development of medicines for use in the older population. https://www.ema.europa.eu

6. European Medicines Agency. (2018). Guideline on pharmaceutical development of medicines for paediatric use. https://www.ema.europa.eu

7. Schering-Plough Corporation. (1993). Claritin product information and loratadine development materials. U.S. regulatory and product records.